Beatrice Claudia Cianciotti, Zulma Irene Magnani, Alessia Ugolini, Barbara Camisa, Ivan Merelli, Valentina Vavassori, Alessia Potenza, Antonio Imparato, Francesco Manfredi, Danilo Abbati, Laura Perani, Antonello Spinelli, Eric Shifrut, Fabio Ciceri, Luca Vago, Raffaella Di Micco, Luigi Naldini, Pietro Genovese, Eliana Ruggiero, Chiara Bonini
BACKGROUND: In adoptive T cell therapy, the long term therapeutic benefits in patients treated with engineered tumor specific T cells are limited by the lack of long term persistence of the infused cellular products and by the immunosuppressive mechanisms active in the tumor microenvironment. Exhausted T cells infiltrating the tumor are characterized by loss of effector functions triggered by multiple inhibitory receptors (IRs). In patients, IR blockade reverts T cell exhaustion but has low selectivity, potentially unleashing autoreactive clones and resulting in clinical autoimmune side effects...
2024: Frontiers in Immunology